Acting on behalf of the Wisequity III closed-end fund, Italy-based Wise SGR has finalised the acquisition of the entire share capital of NTC, an Italian pharmaceuticals company operating in the generic pharmaceuticals, medications and nutraceuticals sectors. The company exports more than 85% of its output to around 55 different countries. This operation forms part of a plan to create an Italian pharmaceuticals group with a strong focus on exports that was set in motion in January 2015 with the acquisition of PH&T. Both companies have interesting “stand alone” development plans that will be accelerated by pooling the international distribution and product development platforms that the companies have developed over the years.